Or seek new ground breaking te

Like
Comment
Favorite

Or seek new ground breaking technology 😜

Do Queasy Side Effects Mean the End of Weight-Loss Drug Stock Hype?

The bloom may be off the rose for obesity drugs as reports of side effects for high doses of GLP-1 drugs. GLP-1s were originally designed to treat diabetes, but showed effectiveness in weigh loss. The

Do Queasy Side Effects Mean the End of Weight-Loss Drug Stock Hype?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":350025386045648,"tweetId":"350025386045648","gmtCreate":1726483325741,"gmtModify":1726483329575,"author":{"id":4186961749712122,"authorId":4186961749712122,"authorIdStr":"4186961749712122","name":"Stoid","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Or seek new ground breaking technology 😜</p></body></html>","htmlText":"<html><head></head><body><p>Or seek new ground breaking technology 😜</p></body></html>","text":"Or seek new ground breaking technology 😜","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/350025386045648","repostId":2467889355,"repostType":2,"repost":{"id":"2467889355","pubTimestamp":1726475900,"share":"https://www.laohu8.com/m/news/2467889355?lang=&edition=full","pubTime":"2024-09-16 16:38","market":"sh","language":"en","title":"Do Queasy Side Effects Mean the End of Weight-Loss Drug Stock Hype?","url":"https://stock-news.laohu8.com/highlight/detail?id=2467889355","media":"Seekingalpha","summary":"The bloom may be off the rose for obesity drugs as reports of side effects for high doses of GLP-1 drugs. GLP-1s were originally designed to treat diabetes, but showed effectiveness in weigh loss. The","content":"<html><head></head><body><p>The bloom may be off the rose for obesity drugs as reports of side effects for high doses of GLP-1 drugs.</p><p>GLP-1s were originally designed to treat diabetes, but showed effectiveness in weigh loss. The space is currently dominated by <a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a>, which makes Zepbound and Mounjaro, and <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, with Ozempic and Wegovy.</p><p>The success of the drugs has helped shares of both companies. NVO is up more than 40% in the past year and LLY is up more than 50%. Both stocks are not far from 52-week highs.</p><p>But the Financial Times reported a recent Roche study showed &#34;high rates of vomiting and other side effects among those who took strong doses of the drugs.&#34;</p><p>Three of four patients on the highest dose of the CT-388 injection experienced vomiting, while the oral pill showed similar side-effects, the FT said. It added that 30% of GLP-1 users stopped within four weeks of taking the drugs, with many citing side effects, according to Blue Health Intelligence.</p><p>The popularity of the drugs has resulted in a race to enter the market. Up to 16 new GLP-1 drugs could be launched by 2029, eventually taking nearly a third of a potential $200B market by 2031, according to a report by Morningstar and Pitchbook.</p><p>Other players in the weight-loss space include <a href=\"https://laohu8.com/S/AMGN\">Amgen</a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, AstraZeneca(AZN)$, Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR), while Merck (MRK) and J&amp;J (JNJ) are potential suitors for a GLP-1 developer.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Do Queasy Side Effects Mean the End of Weight-Loss Drug Stock Hype?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDo Queasy Side Effects Mean the End of Weight-Loss Drug Stock Hype?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-16 16:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4149819-do-nauseating-side-effects-mean-the-end-of-weight-loss-drug-stock-hype><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The bloom may be off the rose for obesity drugs as reports of side effects for high doses of GLP-1 drugs.GLP-1s were originally designed to treat diabetes, but showed effectiveness in weigh loss. The ...</p>\n\n<a href=\"https://seekingalpha.com/news/4149819-do-nauseating-side-effects-mean-the-end-of-weight-loss-drug-stock-hype\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4550":"红杉资本持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4568":"美国抗疫概念","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0079474960.USD":"联博美国增长基金A","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","BK4559":"巴菲特持仓","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LLY":"礼来","LU0058720904.USD":"联博国际健康护理基金A","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0882574055.USD":"富达全球健康医疗A ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","NVO":"诺和诺德","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","BK4566":"资本集团","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC"},"source_url":"https://seekingalpha.com/news/4149819-do-nauseating-side-effects-mean-the-end-of-weight-loss-drug-stock-hype","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2467889355","content_text":"The bloom may be off the rose for obesity drugs as reports of side effects for high doses of GLP-1 drugs.GLP-1s were originally designed to treat diabetes, but showed effectiveness in weigh loss. The space is currently dominated by Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, with Ozempic and Wegovy.The success of the drugs has helped shares of both companies. NVO is up more than 40% in the past year and LLY is up more than 50%. Both stocks are not far from 52-week highs.But the Financial Times reported a recent Roche study showed \"high rates of vomiting and other side effects among those who took strong doses of the drugs.\"Three of four patients on the highest dose of the CT-388 injection experienced vomiting, while the oral pill showed similar side-effects, the FT said. It added that 30% of GLP-1 users stopped within four weeks of taking the drugs, with many citing side effects, according to Blue Health Intelligence.The popularity of the drugs has resulted in a race to enter the market. Up to 16 new GLP-1 drugs could be launched by 2029, eventually taking nearly a third of a potential $200B market by 2031, according to a report by Morningstar and Pitchbook.Other players in the weight-loss space include Amgen, Pfizer, AstraZeneca(AZN)$, Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR), while Merck (MRK) and J&J (JNJ) are potential suitors for a GLP-1 developer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":29,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":35,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}